Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors

  • Huang J
  • Moore J
  • Soffer S
 et al. 
  • 3


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


BACKGROUND/PURPOSE: Pathologic angiogenesis in tumors is a potential target for novel therapies. Vascular endothelial growth factor (VEGF) is an angiogenic promoter present in a wide variety of human tumors. VEGF is expressed as 4 isoforms; one of these, VEGF165, predominates in human tumors. The authors hypothesized that antagonism of VEGF165 by a specific aptamer would block tumor growth in an experimental model of Wilms tumor. METHODS: VEGF isoform expression in clinical (n = 2) and experimental tumors were evaluated by reverse transcription polymerase chain reaction (RT-PCR). Tumors were induced in NCR nude mice (n = 32) by intrarenal injection of 10(6) cultured Wilms tumor cells. At 1 week, aptamer (n = 16) or vehicle (n = 16) treatment was started and continued daily for 5 weeks. RESULTS: At 6 weeks tumors weighed 84% less in treated versus control animals (0.69 v 4.41 g; P

Author-supplied keywords

  • Angiogenesis Inhibitors/*therapeutic use
  • Animals
  • Endothelial Growth Factors/antagonists & inhibitor
  • Kidney Neoplasms/*therapy
  • Mice
  • Models, Animal
  • Reverse Transcriptase Polymerase Chain Reaction
  • Treatment Outcome
  • Tumor Cells, Cultured
  • Wilms Tumor/*therapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • J Huang

  • J Moore

  • S Soffer

  • E Kim

  • D Rowe

  • C A Manley

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free